1. Home
  2. RBC vs VRNA Comparison

RBC vs VRNA Comparison

Compare RBC & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RBC
  • VRNA
  • Stock Information
  • Founded
  • RBC 1919
  • VRNA 2005
  • Country
  • RBC United States
  • VRNA United Kingdom
  • Employees
  • RBC N/A
  • VRNA N/A
  • Industry
  • RBC Metal Fabrications
  • VRNA Biotechnology: Pharmaceutical Preparations
  • Sector
  • RBC Industrials
  • VRNA Health Care
  • Exchange
  • RBC Nasdaq
  • VRNA Nasdaq
  • Market Cap
  • RBC 9.7B
  • VRNA 7.8B
  • IPO Year
  • RBC 2005
  • VRNA 2017
  • Fundamental
  • Price
  • RBC $372.92
  • VRNA $92.20
  • Analyst Decision
  • RBC Buy
  • VRNA Strong Buy
  • Analyst Count
  • RBC 6
  • VRNA 7
  • Target Price
  • RBC $390.20
  • VRNA $97.57
  • AVG Volume (30 Days)
  • RBC 161.2K
  • VRNA 1.4M
  • Earning Date
  • RBC 08-01-2025
  • VRNA 08-07-2025
  • Dividend Yield
  • RBC N/A
  • VRNA N/A
  • EPS Growth
  • RBC 20.13
  • VRNA N/A
  • EPS
  • RBC 7.70
  • VRNA N/A
  • Revenue
  • RBC $1,636,300,000.00
  • VRNA $118,535,000.00
  • Revenue This Year
  • RBC $8.90
  • VRNA $891.79
  • Revenue Next Year
  • RBC $7.91
  • VRNA $78.94
  • P/E Ratio
  • RBC $48.25
  • VRNA N/A
  • Revenue Growth
  • RBC 4.87
  • VRNA N/A
  • 52 Week Low
  • RBC $260.53
  • VRNA $14.14
  • 52 Week High
  • RBC $386.41
  • VRNA $94.45
  • Technical
  • Relative Strength Index (RSI)
  • RBC 57.22
  • VRNA 78.05
  • Support Level
  • RBC $363.05
  • VRNA $82.18
  • Resistance Level
  • RBC $375.31
  • VRNA $93.74
  • Average True Range (ATR)
  • RBC 7.97
  • VRNA 3.21
  • MACD
  • RBC -1.73
  • VRNA 0.89
  • Stochastic Oscillator
  • RBC 56.41
  • VRNA 92.52

About RBC RBC Bearings Incorporated

RBC Bearings Inc is an international manufacturer and marketer of highly engineered precision bearings, components and essential systems for the industrial, defense and aerospace industries. The offering includes plain bearings, roller bearings, ball bearings, and engineered products. The end market is the United States of America. The company has two reportable segments: Aerospace Defense segment represents the end markets for the company's highly engineered bearings and precision components used in commercial aerospace, defense aerospace, and sea and ground defense applications; and Industrial segment represents the end markets for the company's engineered bearings and precision components used in various industrial applications. It derives maximum revenue from Industrial Segment.

About VRNA Verona Pharma plc

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

Share on Social Networks: